One trial (NCT04107142) is a dose escalation trial for CAR-T cells targeting NKG2DL thought to be important in the regulation of tumor progression, and the other (NCT03970382) is testing neoantigen targeted TCR on locally advanced or metastatic tumors.52 One other trial is active (NCT02757391) and is testing a CD8+ T-cell therapy with pembrolizumab, the immune checkpoint PD-1 inhibitor, while the remaining 2 other trials registered on ClinicalTrials.gov were terminated due to feasibility and sponsor decision. This evidence concerns the gene PDCD1 and neoplasm.